Hearing Loss, Reversed

A therapy for sensorineural hearing loss could be on the horizon from Frequency Therapeutics, founded on regenerative biology research by MIT Institute Professor Robert Langer ScD ’74 and former Langer Lab postdoc Jeffrey Karp, whose affiliations include Harvard, Brigham and Women’s Hospital, and the Broad Institute, and who teaches in the Harvard-MIT Health Sciences and Technology Program. Under CEO David Lucchino MBA ’06 and chief scientific officer Chris Loose PhD ’07, Frequency has successfully completed a first-in-human safety study of a small-molecule drug intended to activate the regrowth of sensory cells in the inner ear.